Treatment with GLP‐1 RA was associated with a reduction of a composite outcome of myocardial infarction, stroke, and all‐cause death compared to DPP‐4i treatment when glycemic control was achieved as indicated by an obtained HbA1c level not exceeding 53 mmol/mol. This evidence concerns the gene GLP1R and myocardial infarction.